Indivior Pharmaceuticals Declares Special Cash Dividend; Merger with Supernus

What Happened

• Indivior Pharmaceuticals, Inc. announced on September 17, 2026 that it has declared a special cash dividend in connection with its proposed merger of equals with Supernus Pharmaceutical Holdings, Inc. The company furnished a press release announcing the dividend as Exhibit 99.1 to its Form 8-K. Indivior and Supernus previously filed a joint proxy statement/prospectus with the SEC on September 11, 2026 regarding the proposed transaction.

Key Details

• Press release announcing the special cash dividend was issued and furnished on September 17, 2026 (Exhibit 99.1 to the Form 8-K).
• A joint proxy statement/prospectus for the proposed merger was filed with the SEC on September 11, 2026.
• The dividend is expected to be paid in connection with the closing of the proposed merger; the 8-K does not state the dividend amount or specific payment date.
• The filing highlights forward‑looking statements and risks, including the need for shareholder and regulatory approvals and the potential use of additional indebtedness to fund the special dividend.

Why It Matters

• For investors, a declared special cash dividend can mean a near‑term cash return, but here the payment is conditional on the merger closing. There is no assurance the merger will complete or the dividend will be paid as described.
• If the dividend is funded with new debt (as the filing notes could occur), that could affect the combined company’s balance sheet and credit profile.
• Retail investors should read the joint proxy statement/prospectus and related SEC filings for full details and risks before making any decisions. Documents are available free at www.sec.gov, Indivior’s investor site (www.indivior.com), and Supernus’ site (www.supernus.com).